Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery

Marie Stark, R. Holland Cheng

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Nanoparticle diagnostics and therapeutics (nanotheranostics) have significantly advanced cancer detection and treatment. However, many nanotheranostics are ineffective due to defects in tumor localization and bioavailability. An engineered Hepatitis E Virus (HEV) nanocapsid is a proposed platform for targeted cancer-cell delivery. Self-assembling from HEV capsid subunits, nanocapsids retain the capacity to enter cells and resist proteolytic/acidic conditions, but lack infectious viral elements. The nanocapsid surface was modified for chemical activation to confer tumor-specific targeting and detection, immune-response manipulation and controlled theranostic delivery. Nanotheranostic molecules can be packaged in the hollow nanocapsid shell during in vitro assembly. Complementing the adapted stability and cell-entry characteristics of the HEV capsid, a modified nanocapsid serves as a tunable tumor-targeting platform for nanotheronostic delivery.

Original languageEnglish (US)
Pages (from-to)307-317
Number of pages11
JournalPharmaceutical patent analyst
Issue number5
StatePublished - Sep 1 2016


  • cancer targeting
  • nanotheranostics
  • viral capsid

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmaceutical Science
  • Drug Discovery


Dive into the research topics of 'Surface modulatable nanocapsids for targeting and tracking toward nanotheranostic delivery'. Together they form a unique fingerprint.

Cite this